San Francisco, CA, United States of America

Colin O'Bryan


Average Co-Inventor Count = 5.3

ph-index = 2

Forward Citations = 6(Granted Patents)


Location History:

  • San Francisco, CA (US) (2013 - 2014)
  • Cardiff, CA (US) (2015)

Company Filing History:


Years Active: 2013-2015

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Colin O'Bryan: Innovator in Pharmaceutical Inventions

Introduction

Colin O'Bryan is a notable inventor based in San Francisco, CA, who has made significant contributions to the field of pharmaceuticals. With a total of three patents to his name, O'Bryan's work focuses on innovative solutions for treating serious medical conditions.

Latest Patents

O'Bryan's latest patents include a novel Factor VIIa inhibitor. This invention relates to inhibitors of Factors VIIa, IXa, Xa, and XIa, with a particular emphasis on Factor VIIa. The pharmaceutical compositions comprising these inhibitors are designed for treating or preventing thromboembolic disorders, cancer, or rheumatoid arthritis. Additionally, the patents disclose processes for preparing these inhibitors, showcasing O'Bryan's commitment to advancing medical science.

Career Highlights

Colin O'Bryan is currently employed at Pharmacyclics, Inc., where he continues to develop groundbreaking pharmaceutical solutions. His expertise and innovative mindset have positioned him as a valuable asset in the industry.

Collaborations

O'Bryan collaborates with talented professionals such as Daniel A Dickman and Dange Vijay Kumar, contributing to a dynamic work environment that fosters innovation and creativity.

Conclusion

Colin O'Bryan's contributions to pharmaceutical inventions, particularly in the area of Factor VIIa inhibitors, highlight his role as a leading inventor in the field. His work not only advances medical treatments but also exemplifies the spirit of innovation in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…